Study quantifies impact of resistant Pseudomonas on outcomes.
Kepple
S R
SR
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001900:Boston; D002442:Ceftazidime / Q000494:pharmacology; D002939:Ciprofloxacin / Q000494:pharmacology; D004352:Drug Resistance, Microbial; D006760:Hospitalization / Q000191:economics*; D006801:Humans; D015378:Imipenem / Q000494:pharmacology; D010878:Piperacillin / Q000494:pharmacology; D011552:Pseudomonas Infections / Q000191:economics*; D011550:Pseudomonas aeruginosa / Q000187:drug effects*
D000900:Anti-Bacterial Agents; D002939:Ciprofloxacin; D015378:Imipenem; D002442:Ceftazidime; D010878:Piperacillin